Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021900
Reexamination Certificate
active
07994127
ABSTRACT:
The invention relates to methods for treatment of Rett Syndrome and other disorders of synaptic function and maturation using IGF1, (1-3)IGF-1, (1-3)IGF-1 analog(s) and/or related therapeutic molecules.
REFERENCES:
patent: 4411890 (1983-10-01), Momany et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5446024 (1995-08-01), Builder et al.
patent: 5565428 (1996-10-01), Clark et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 6331414 (2001-12-01), Lee et al.
patent: 6559150 (2003-05-01), Carpino et al.
patent: 7041314 (2006-05-01), Abood et al.
patent: 7304029 (2007-12-01), Scheepens et al.
patent: 2002/0013277 (2002-01-01), Gluckman et al.
patent: 2002/0160384 (2002-10-01), Ashkenazi et al.
patent: 2002/0160955 (2002-10-01), Dubaquie et al.
patent: 2002/0165155 (2002-11-01), Schaffer et al.
patent: 2003/0055004 (2003-03-01), Abood et al.
patent: 2005/0059598 (2005-03-01), Clark et al.
patent: 2006/0064249 (2006-03-01), Clark et al.
patent: 2006/0100287 (2006-05-01), Okajima et al.
patent: 2006/0217295 (2006-09-01), Harris et al.
patent: 2007/0224165 (2007-09-01), Guan et al.
patent: 2008/0145335 (2008-06-01), Brimble et al.
patent: 0 366 638 (1990-05-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 02/16408 (2002-02-01), None
patent: WO 02/056873 (2002-07-01), None
patent: WO 02/057241 (2002-07-01), None
patent: WO 2005/009394 (2005-02-01), None
patent: WO 2006/130769 (2006-12-01), None
patent: WO 2007/120847 (2007-10-01), None
Xing et al. (Exp. Neurology 205: 222-229, 2007).
Gemelli et al. (Biol. Psychiatry 59: 468-476, 2006).
Huppke et al. Acta Paediatr. 90: 1257-1261, 2001.
Tropea et al. PNAS 106(6): 2029-2034, 2009.
Kaufmann et al. Brain & Development 27: S77-S87, 2005.
Aberg et al., Peripheral infusion of IGf-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci. Apr. 15, 2000;20(8):2896-903.
Bondy, Transient IGF-I gene expression during the maturation of functionally related central projection neurons. J Neurosci. Nov. 1991;11(11):3442-55.
Chahrour et al., The story of Rett syndrome: from clinic to neurobiology. Neuron. Nov. 8, 2007;56(3):422-37. Review.
Chang et al., The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. Feb. 2, 2006;49(3):341-8.
Chao et al., MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron. Oct. 4, 2007;56(1):58-65.
Dani et al., Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A. Aug. 30, 2005;102(35):12560-5. Epub Aug 22, 2005.
Doré et al., Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci. Aug. 1997;20(8):326-31. Review.
Giacometti et al., Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A. Feb. 6, 2007;104(6):1931-6. Epub Jan. 31, 2007.
Gordon et al., Experience-dependent plasticity of binocular responses in the primary visual cortex of the mouse. J Neurosci. May 15, 1996;16(10):3274-86.
Nelson et al., MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. Curr Biol. Apr. 4, 2006;16(7):710-6.
Ramsey et al., Functional characterization of des-IGF-1 action at excitatory synapses in the CA1 region of rat hippocampus. J Neurophysiol. Jul. 2005;94(1):247-54.
Riikonen et al., Cerebrospinal fluid insulin-like growth factors IGF-1 and IGF-2 in infantile autism. Dev Med Child Neurol. Sep. 2006;48(9):751-5.
Riikonen, Insulin-like growth factor delivery across the blood-brain barrier. Potential use of IGF-1 as a drug in child neurology. Chemotherapy. 2006;52(6):279-81. Epub Sep 27, 2006.
Shahbazian et al., Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. Jul. 18, 2002;35(2):243-54.
Shahbazian et al., Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet. Jan. 15, 2002;11(2):115-24.
Tudor et al., Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A. Nov. 26, 2002;99(24):15536-41. Epub Nov. 13, 2002.
Zheng et al., Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J Neurochem. May 2004;89(4):844-52.
Aberg et al., IGF-I has a direct proliferative effect in adult hippocampal progenitor cells. Mol Cell Neurosci. Sep. 2003;24(1):23-40.
Acampa et al., Cardiac disease and Rett syndrome. Arch Dis Child. May 2006;91(5):440-443. Review.
Amir et al., Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. Oct. 1999;23(2):185-188.
Ankersen et al., Demonstration of the strength of focused combinatorial libraries in SAR optimization of growth hormone secretagogues. Eur J Med Chem. Oct. 1999;34(10):783-790.
Ankersen et al., Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal. Eur J Med Chem. May 2000; 35(5):487-497.
Baker et al., Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides. Apr. 2005;39(2):81-7. Epub Jan. 28, 2005.
Ciucci et al., Insulin-like growth factor 1 (IGF-1) mediates the effects of enriched environment (EE) on visual cortical development. PLoS One. May 30, 2007;2(5):e475.
Chen et al., Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. Mar. 2001;27(3):327-31.
Chen et al., Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. Oct. 31, 2003;302(5646):885-9.
Cohen et al., Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis. Mol Cell Neurosci. Apr. 2003;22(4):417-429.
El-Husseini et al., PSD-95 involvement in maturation of excitatory synapses. Science. Nov. 17, 2000;290(5495):1364-1368.
Guan et al., Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology. Nov. 2004;47(6):892-903.
Guy et al., Reversal of neurological defects in a mouse model of Rett syndrome. Science. Feb. 23, 2007 23;315(5815):1143-7. Epub Feb. 8, 2007.
Guy et al., A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. Mar. 2001;27(3):322-326.
Hofer et al., Prior experience enhances plasticity in adult visual cortex. Nat Neurosci. Jan. 2006;9(1):127-32. Epub Dec. 4, 2005.
Itoh et al., Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. J Neuropathol Exp Neurol. Feb. 2007;66(2):117-23.
Johnston et al., Neurobiology of Rett syndrome: a genetic disorder of synapse development. Brain Dev. Dec. 2001;23 Suppl 1:S206-S213. Review.
Julu et al., Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder. Arch Dis Child. Jul. 2001;85(1):29-37.
Kaufmann et al., Abnormalities in neuronal maturation in Rett syndrome neocortex: preliminary molecular correlates. Eur Child Adolesc Psychiatry. 1997;6 Suppl 1:75-7. Erratum in: Eur Child Adolesc Psychiatry Jun. 1998;7(2):124.
Langer, New methods of drug delivery. Science. Sep. 28, 1990;249(4976):1527-1533. Review.
Lee et al., Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J Biol Chem. May 6, 2005;280(18):18543-50. Epub Mar. 8, 2005.
Liu et al., Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. Oct. 8, 1993;75(1):59-72.
L
Giacometti Emanuela
Jaenisch Rudolf
Sur Mriganka
Tropea Daniela
Wilson Nathan R.
Massachusetts Institute of Technology
Saoud Christine J
Whitehead Institute of Biomedical Research
Wolf Greenfield & Sacks P.C.
LandOfFree
Treatment of rett syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of rett syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of rett syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726526